Signs of a shakeout in the Indian CRO segment are growing clearer, with a number of small and mid-sized units apparently having scaled down or put themselves on the block.
If a clutch of industry heads and investment bankers is to be believed, then fringe and smaller firms largely focused on bioavailability and bioequivalence (BA/BE) studies are already feeling the pinch
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?